CoChat

Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study

Brocklebank, Vicky, Walsh, Patrick R., Smith-Jackson, Kate, Hallam, Thomas M., Marchbank, Kevin J., Wilson, Valerie, Bigirumurame, Theophile, Dutt, Tina, Montgomery, Emma K., Malina, Michal, Wong, Edwin K. S., Johnson, Sally, Sheerin, Neil S., Kavanagh, David · 2023 · Blood
Cited by 85

The DOI matches its Crossref record.

Abstract

Historically, the majority of patients with complement-mediated atypical hemolytic uremic syndrome (CaHUS) progress to end-stage kidney disease (ESKD). Single-arm trials of eculizumab with a short follow-up suggested efficacy. We prove, for the first time to our knowledge, in a genotype matched CaHUS cohort that the 5-year cumulative estimate of ESKD-free survival improved from 39.5% in a control cohort to 85.5% in the eculizumab-treated cohort (hazard ratio, 4.95; 95% confidence interval [CI], 2.75-8.90; P = .000; number needed to treat, 2.17 [95% CI, 1.81-2.73]). The outcome of eculizumab treatment is associated with the underlying genotype. Lower serum creatinine, lower platelet count, lower blood pressure, and younger age at presentation as well as shorter time between presentation and the first dose of eculizumab were associated with estimated glomerular filtration rate >60 ml/min at 6 months in multivariate analysis. The rate of meningococcal infection in the treated cohort was 550 times greater than the background rate in the general population. The relapse rate upon eculizumab withdrawal was 1 per 9.5 person years for patients with a pathogenic mutation and 1 per 10.8 person years for those with a variant of uncertain significance. No relapses were recorded in 67.3 person years off eculizumab in those with no rare genetic variants. Eculizumab was restarted in 6 individuals with functioning kidneys in whom it had been stopped, with no individual progressing to ESKD. We demonstrated that biallelic pathogenic mutations in RNA-processing genes, including EXOSC3, encoding an essential part of the RNA exosome, cause eculizumab nonresponsive aHUS. Recessive HSD11B2 mutations causing apparent mineralocorticoid excess may also present with thrombotic microangiopathy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2022018833

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 51

  1. Brocklebank, 2018, Thrombotic microangiopathy and the kidney, Clin J Am Soc Nephrol, 13, 300, 10.2215/CJN.00620117 · DOI · Paper page
  2. Goodship, 2017, Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "kidney disease: improving global outcomes" (KDIGO) controversies conference, Kidney Int, 91, 539, 10.1016/j.kint.2016.10.005 · DOI · Paper page
  3. Noris, 2010, Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype, Clin J Am Soc Nephrol, 5, 1844, 10.2215/CJN.02210310 · DOI · Paper page
  4. Legendre, 2013, Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome, N Engl J Med, 368, 2169, 10.1056/NEJMoa1208981 · DOI · Paper page
  5. Licht, 2015, Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies, Kidney Int, 87, 1061, 10.1038/ki.2014.423 · DOI · Paper page
  6. Greenbaum, 2016, Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome, Kidney Int, 89, 701, 10.1016/j.kint.2015.11.026 · DOI · Paper page
  7. Sheerin, 2016, A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience, QJM, 109, 27, 10.1093/qjmed/hcv082 · DOI
  8. Warwicker, 1998, Genetic studies into inherited and sporadic hemolytic uremic syndrome, Kidney Int, 53, 836, 10.1111/j.1523-1755.1998.00824.x · doi:10.1111/j.1523-1755.1998.00824.x · Paper page
  9. Glover, 2023, Assessing the impact of prophylactic eculizumab on renal graft survival in atypical haemolytic uraemic syndrome, Transplantation, 107, 994, 10.1097/TP.0000000000004355 · DOI
  10. Brocklebank, 2017, Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland, Kidney Int, 92, 1261, 10.1016/j.kint.2017.04.028 · DOI
  11. Brocklebank, 2020, Long-term outcomes and response to treatment in DGKE nephropathy, Kidney Int, 97, 1260, 10.1016/j.kint.2020.01.045 · DOI
  12. Challis, 2016, A de novo deletion in the regulators of complement activation cluster producing a hybrid complement factor H/complement factor H-related 3 gene in atypical hemolytic uremic syndrome, J Am Soc Nephrol, 27, 1617, 10.1681/ASN.2015010100 · DOI
  13. Fremeaux-Bacchi, 2008, Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome, Blood, 112, 4948, 10.1182/blood-2008-01-133702 · DOI · Paper page
  14. Gleeson, 2016, Chromosomal rearrangement-A rare cause of complement factor I associated atypical haemolytic uraemic syndrome, Immunobiology, 221, 1124, 10.1016/j.imbio.2016.05.002 · DOI
  15. Kavanagh, 2005, Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome, J Am Soc Nephrol, 16, 2150, 10.1681/ASN.2005010103 · DOI · Paper page
  16. Kavanagh, 2006, Does complement factor B have a role in the pathogenesis of atypical HUS?, Mol Immunol, 43, 856, 10.1016/j.molimm.2005.06.041 · doi:10.1016/j.molimm.2005.06.041
  17. Richards, 2001, Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition, Am J Hum Genet, 68, 485, 10.1086/318203 · DOI · Paper page
  18. Richards, 2003, Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome, Proc Natl Acad Sci U S A, 100, 12966, 10.1073/pnas.2135497100 · DOI · Paper page
  19. Kavanagh, 2012, Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?, Clin J Am Soc Nephrol, 7, 417, 10.2215/CJN.05750611 · DOI
  20. Moore, 2010, Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome, Blood, 115, 379, 10.1182/blood-2009-05-221549 · DOI · Paper page
  21. Challis, 2017, Thrombotic microangiopathy in inverted formin 2-mediated renal disease, J Am Soc Nephrol, 28, 1084, 10.1681/ASN.2015101189 · DOI
  22. Hallam, 2022, A novel method for real-time analysis of the complement C3b:FH:FI complex reveals dominant negative CFI variants in age-related macular degeneration, Front Immunol, 13, 1028760, 10.3389/fimmu.2022.1028760 · DOI
  23. Kavanagh, 2008, Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome, Mol Immunol, 45, 95, 10.1016/j.molimm.2007.05.004 · DOI
  24. Richards, 2007, Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome, Mol Immunol, 44, 111, 10.1016/j.molimm.2006.07.004 · DOI
  25. Public Health England, 2019, Invasive meningococcal disease in England: annual laboratory confirmed reports for epidemiological year 2018/2019, Health Protection Report, 13
  26. Fakhouri, 2020, Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group, Blood, 136, 2103, 10.1182/blood.2020005221 · DOI · Paper page
  27. Bruel, 2017, Hemolytic uremic syndrome in pregnancy and postpartum, Clin J Am Soc Nephrol, 12, 1237, 10.2215/CJN.00280117 · DOI · Paper page
  28. Rondeau, 2020, The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment, Kidney Int, 97, 1287, 10.1016/j.kint.2020.01.035 · DOI
  29. Barbour, 2021, Long-term efficacy and safety of the long-acting complement c5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults, Kidney Int Rep, 6, 1603, 10.1016/j.ekir.2021.03.884 · DOI
  30. Fakhouri, 2016, Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial, Am J Kidney Dis, 68, 84, 10.1053/j.ajkd.2015.12.034 · DOI · Paper page
  31. Caprioli, 2006, Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome, Blood, 108, 1267, 10.1182/blood-2005-10-007252 · DOI · Paper page
  32. Walle, 2017, Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment, J Nephrol, 30, 127
  33. Chawla, 2017, Acute kidney disease and renal recovery: consensus report of the acute disease quality initiative (ADQI) 16 workgroup, Nat Rev Nephrol, 13, 241, 10.1038/nrneph.2017.2 · DOI · Paper page
  34. Manenti, 2013, Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature, Nephrol Dial Transplant, 28, 2246, 10.1093/ndt/gft220 · DOI
  35. Dave-Sharma, 1998, Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess1, J Clin Endocrinol Metab, 83, 2244
  36. Muller, 2020, RNA exosome mutations in pontocerebellar hypoplasia alter ribosome biogenesis and p53 levels, Life Sci Alliance, 3, e202000678, 10.26508/lsa.202000678 · DOI · Paper page
  37. Tesh, 2012, Activation of cell stress response pathways by Shiga toxins, Cell Microbiol, 14, 1, 10.1111/j.1462-5822.2011.01684.x · DOI · Paper page
  38. Walsh, 2018, Glucose-6-phosphate dehydrogenase deficiency mimicking atypical hemolytic uremic syndrome, Am J Kidney Dis, 71, 287, 10.1053/j.ajkd.2017.08.007 · DOI
  39. Ferreira, 2009, The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome, J Immunol, 182, 7009, 10.4049/jimmunol.0804031 · DOI · Paper page
  40. Kavanagh, 2013, Atypical hemolytic uremic syndrome, Semin Nephrol, 33, 508, 10.1016/j.semnephrol.2013.08.003 · DOI · Paper page
  41. Bu, 2018, Genetic analysis of 400 patients refines understanding and implicates a new gene in atypical hemolytic uremic syndrome, J Am Soc Nephrol, 29, 2809, 10.1681/ASN.2018070759 · DOI
  42. Fremeaux-Bacchi, 2013, Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults, Clin J Am Soc Nephrol, 8, 554, 10.2215/CJN.04760512 · DOI · Paper page
  43. Delvaeye, 2009, Thrombomodulin mutations in atypical hemolytic-uremic syndrome, N Engl J Med, 361, 345, 10.1056/NEJMoa0810739 · DOI · Paper page
  44. Cavero, 2019, Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome, Kidney Int, 96, 995, 10.1016/j.kint.2019.05.014 · DOI
  45. Timmermans, 2020, Diagnostic and risk factors for complement defects in hypertensive emergency and thrombotic microangiopathy, Hypertension, 75, 422, 10.1161/HYPERTENSIONAHA.119.13714 · DOI
  46. Azukaitis, 2017, The phenotypic spectrum of nephropathies associated with mutations in diacylglycerol kinase epsilon, J Am Soc Nephrol, 28, 3066, 10.1681/ASN.2017010031 · DOI
  47. Fakhouri, 2021, Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study, Blood, 137, 2438, 10.1182/blood.2020009280 · DOI · Paper page
  48. Dunn, 2022, Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study, BMJ Open, 12, e054536, 10.1136/bmjopen-2021-054536 · DOI
  49. Bouwmeester, 2023, Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study, Kidney Int Rep, 8, 91, 10.1016/j.ekir.2022.10.013 · DOI
  50. Ardissino, 2015, Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update, Am J Kidney Dis, 66, 172, 10.1053/j.ajkd.2015.04.010 · doi:10.1053/j.ajkd.2015.04.010
  51. Merrill, 2017, Eculizumab cessation in atypical hemolytic uremic syndrome, Blood, 130, 368, 10.1182/blood-2017-02-770214 · DOI

Cited by

See all 85

Metadata

Authors
Brocklebank, V., Walsh, P. R., Smith-Jackson, K., Hallam, T. M., Marchbank, K. J., Wilson, V., Bigirumurame, T., Dutt, T., Montgomery, E. K., Malina, M., Wong, E. K. S., Johnson, S., Sheerin, N. S., & Kavanagh, D.
Affiliations
  • 1National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom
  • 2Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
  • 3Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
  • 4Department of Haematology, Royal Liverpool University Hospital, Liverpool, United Kingdom
Venue
Blood
Published
2023-10-19
Volume
142
Issue
16
Pages
1371-1386
ISSN
  • 0006-4971
  • 1528-0020
Cited by
85
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study. https://app.cochat.ai/papers/10.1182/blood.2022018833
The paper
Brocklebank, V., Walsh, P. R., Smith-Jackson, K., Hallam, T. M., Marchbank, K. J., Wilson, V., Bigirumurame, T., Dutt, T., Montgomery, E. K., Malina, M., Wong, E. K. S., Johnson, S., Sheerin, N. S., & Kavanagh, D. (2023). Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study. Blood. https://doi.org/10.1182/blood.2022018833

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.